<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Merck has introduced AIDDISON, the first-ever AI-powered software-as-a-service product that integrates the discovery and synthesis of drugs. The platform combines GenAI, machine learning, and computer-aided drug design technologies.
      </p>
    </li>
    <li>
      <p>
        The software leverages datasets from approximately 20 years of pharmaceutical R&amp;D, and it can select compounds from over 60 billion possibilities that possess vital properties for a successful drug, such as non-toxicity, solubility, and body stability. The software also suggests optimal methods for drug synthesis.
      </p>
    </li>
    <li>
      <p>
        Merck also states that AI has the potential to save up to 70% time and cost involved in the drug discovery process and could offer savings of more than USD 70 billion by 2028.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/in/news-releases/merck-launches-first-ever-ai-solution-to-integrate-drug-discovery-and-synthesis-302003351.html">
      Press release
    </a>
  </p>
  <p>
    <a href="https://www.outsourcing-pharma.com/Article/2023/12/11/Merck-launches-SaaS-platform-with-60-billion-possibilities">
      Outsourcing Pharma
    </a>
  </p>
  <p>
  </p>
</div>


AI Drug Discovery

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 
<p>Merck has launched AIDDISON, a breakthrough AI-SaaS product transforming drug discovery and synthesis. Utilising technologies like GenAI and machine learning, the platform scrutinises almost 20 years' worth of pharmaceutical data and can identify viable compounds from over 60 billion options. It considers crucial properties needed for a successful drug and suggests best practices for drug synthesis. Merck suggests that AI could save up to 70% of the time and cost in drug discovery, potentially resulting in savings of over USD 70 billion by 2028.</p>
 
</div>

Merck unveils new AI SaaS product for drug discovery and synthesis

Israeli AI drug discovery company Quris-AI has extended its partnership with pharma company Merck KGaA to focus on identifying liver toxicity risks in drug candidates. Quris-AI's platform will be utilized to predict drug toxicity, with Merck KGaA having the option to obtain an exclusive license for a specific disease area. In exchange, Quris-AI may receive an undisclosed amount. The collaboration aims to reduce the need for animal testing and enhance the effectiveness of drug development and testing processes.

Quris-AI and Merck expand existing partnership for drug toxicity prediction

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

AI drug discovery companies BenevolentAI and Exscientia have partnered with pharmaceutical company Merck to identify and develop new compounds for drug development. BenevolentAI will use its AI platform and chemistry design tools to deliver small molecule drug development candidates for Merck, with upfront and milestone payments of up to $594 million and royalties on any commercialized products. Exscientia will combine its AI-driven precision drug design capabilities with Merck’s disease expertise in oncology and neuroinflammation, receiving an upfront payment of $20 million and potential milestone payments of up to $674 million, as well as royalty payments on net sales.

Merck enters into drug discovery partnerships with BenevolentAI and Exscientia

BenevolentAI and Exscientia have partnered with pharmaceutical company Merck to identify and develop new compounds against three targets provided by Merck. BenevolentAI's AI platform will be used to identify and develop novel compounds for drug development in the fields of oncology, neurology, and immunology. In return, BenevolentAI will receive upfront and milestone payments of up to $594 million, as well as royalties on net sales. Exscientia will also work with Merck to discover small molecule drug candidates using AI-driven precision drug design capabilities, receiving an upfront cash payment of $20 million and potential milestone payments of up to $674 million, as well as royalty payments.

All Updates

Merck unveils new AI SaaS product for drug discovery and synthesis

Quris-AI and Merck expand existing partnership for drug toxicity prediction

Merck enters into drug discovery partnerships with BenevolentAI and Exscientia

Merck enters into drug discovery partnerships with BenevolentAI and Exscientia

Guardant Health expands its partnership with Merck KGaA to expand the use of its database platform

Merck partners with Orian to develop OMD-208 drug candidate

Standigm and Merck Korea to collaborate for AI drug discovery research

Quris partners with Merck to assess clinical safety prediction solution

Siemens partners with Merck to boost digital trust in industrial value chains

Evaxion Biotech teams up with Merck’s Keytruda